Skip to main content
. 2021 Feb 12;10(2):383. doi: 10.3390/cells10020383

Figure 5.

Figure 5

Secondary end points in phase 2 clinical trial of teprotumumab. (A) Changes in proptosis over time from baseline. (B) Changes in CAS over time from baseline. (C) Post hoc analysis showing fraction of patients achieving 0–1 CAS as a function of time. (C) Change in QOL visual functioning subscale (GO-QOL). (D) GO-QOL visual functioning subscale. (E) Change in GO-QOL appearance subscale. (F) Diplopia responses. From Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–1761. Reprinted with permission from ref. [99]. Copyright Massachusetts Medical Society.